What side effects are associated with this type of intervention?

The most common treatments for Cannabis Use Disorder include behavioral interventions such as Cognitive-Behavioral Therapy (CBT) and Motivational Enhancement Therapy (MET). These therapies are generally well-tolerated with minimal side effects. However, some patients may experience transient discomfort related to the introspective and emotional nature of the therapy sessions. Other treatments, such as the use of medications like topiramate and varenicline, have been associated with side effects including impaired concentration, dizziness, anxiety, and nausea. Gabapentin, another medication used for CUD, may cause headaches, insomnia, and mood changes. Overall, behavioral interventions like the Text-Delivered Counseling Program are preferred due to their lower risk of adverse effects compared to pharmacological treatments.

What prior FDA approvals exist?

As of now, there are no FDA-approved medications specifically for the treatment of Cannabis Use Disorder. Behavioral interventions, such as the Text-Delivered Counseling Program being studied, are the primary approach. These interventions often include cognitive-behavioral therapy (CBT), motivational enhancement therapy (MET), and other forms of counseling. While medications are not approved, ongoing research continues to explore effective treatments for this condition.

What other types of research exist?

Promising, novel alternatives to text-delivered counseling programs for Cannabis Use Disorder patients include: 1) Web-based self-help interventions supplemented by brief chat counseling, which have shown significant improvements in self-reported abstinence rates. 2) Mail-based interventions using cognitive-behavioral and motivational interviewing principles, which are feasible for those in rural or remote areas. 3) Digital self-help interventions, such as internet-based guided self-help programs, which have demonstrated efficacy in reducing cannabis use and improving clinical outcomes.

← Back to Search

Behavioral Intervention

Text-Delivered Counseling for Cannabis Use Disorder

N/A

Waitlist Available

Led By Michael J Mason, Ph.D.

Research Sponsored by The University of Tennessee, Knoxville

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age between 18 to 25 years old

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 1 month, 3 months, 6 months

Awards & highlights

Study Summary

This trial tests a text-delivered counseling program to see if it can stop or reduce cannabis use among young adults.

Who is the study for?

This trial is for young adults aged 18 to 25 who frequently use cannabis and live in Tennessee or Colorado. Participants must show signs of cannabis use disorder, have a positive urine test for cannabis, and be able to communicate in English. They should not have received substance abuse treatment recently and must have access to a text-capable phone.Check my eligibility

What is being tested?

The study is examining the effectiveness of a counseling program delivered through text messages aimed at helping young adults reduce or stop their cannabis use.See study design

What are the potential side effects?

Since this intervention involves counseling via text message, there are no direct medical side effects associated with traditional drug treatments. However, participants may experience psychological discomfort when discussing their substance use.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 25 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 1 month, 3 months, 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 1 month, 3 months, 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1 month, 3 months, 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change from Baseline in Tetrahydrocannabinol (Delta-9-THC-COOH) levels

Change in Past 30-Day Cannabis Use

Secondary outcome measures

Change in Environmental Risk Assessment

Change in Young Adult Social Network Assessment

Cost Measures

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: InterventionExperimental Treatment1 Intervention

Participants randomized to the Intervention group will complete questionnaires at baseline, 1 month, 3 months, and 6 months and will receive 4 weeks of the PNC-txt intervention.

Group II: Waitlist ControlActive Control1 Intervention

Participants randomized to the waitlist control group will complete questionnaires at baseline, 1 month, 3 months, and 6 months.

0 / 1Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for Cannabis Use Disorder (CUD) include behavioral interventions such as Cognitive-Behavioral Therapy (CBT) and Motivational Enhancement Therapy (MET). These therapies help patients identify and modify problematic behaviors and thought patterns related to cannabis use, enhance their motivation to quit, and develop coping strategies to manage triggers and cravings. This approach is crucial for CUD patients as it addresses the psychological aspects of addiction, which are essential for achieving long-term recovery and preventing relapse.

Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence.Five outpatient treatment models for adolescent marijuana use: a description of the Cannabis Youth Treatment Interventions.